Full-Time

Principal Software Engineer

Updated on 8/1/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Software Engineering (1)
Required Skills
Kubernetes
Python
ERP
Distributed Systems
Public Speaking
Apache Spark
SQL
Apache Kafka
OpenAI
MLflow
Docker
RAG
Microservices
AWS
JIRA
Scala
LangGraph
Observability
REST APIs
LangChain
Confluence
DevOps
Databricks

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Master's or Bachelor's degree in Computer Science, Engineering, or equivalent practical experience.
  • 13-17 years of engineering experience building or platforming cloud services or developer platforms, with 3+ years leading engineering teams or technical programs.
  • Proven experience designing and operating cloud-native platforms using Kubernetes, containers, microservices, and related distributed system patterns.
  • Hands-on experience with LLM serving or adjacent model-serving patterns, including inference endpoints, routing, scaling, batching, and latency/cost optimization.
  • Practical knowledge of API gateway patterns, authentication and authorization, and secure integrations.
  • Familiarity with cost attribution and FinOps concepts for cloud and AI workloads.
  • Strong track record partnering with product managers and senior technical stakeholders to deliver platform capabilities and roadmaps.
  • Excellent communication skills with the ability to explain technical tradeoffs clearly to both technical and non-technical audiences.
  • Experience with observability and SRE practices, including metrics, tracing, logging, incident management, and production support.
  • The candidate should have direct experience with manufacturing or industrial technology environments and strong fluency in modern AI and data platforms.
Responsibilities
  • Define the technical vision and reference architecture for AI platforms supporting chatbots, agents, orchestration, and related enterprise services.
  • Translate product and business requirements into scalable platform capabilities, including agent hosting, model access, AI gateways, observability, and operational tooling.
  • Drive platform decisions around LLM serving, model endpoints, caching, batching, latency-versus-cost tradeoffs, and multi-model support.
  • Lead architecture for manufacturing integrations and industrial data connectivity, including patterns for SCADA, Data Historian, MES, ERP, LIMS, APIs, event streams, and document-based knowledge sources.
  • Own platform reliability, scalability, and cost by defining SLIs/SLOs, capacity planning, cost attribution, and FinOps practices.
  • Collaborate with Product Owners, Principal Engineers, and stakeholders to define roadmap, acceptance criteria, and delivery milestones.
  • Lead and mentor engineers delivering platform services, integrations, CI/CD for agents and models, and marketplace/catalog capabilities.
  • Establish standards for security, compliance, and model governance, including data handling, access controls, logging, auditability, and traceability.
  • Be hands-on when needed to prototype architectures, review designs, troubleshoot production incidents, and participate in code and design reviews.
Desired Qualifications
  • Direct experience with manufacturing applications, industrial data platforms, or regulated manufacturing environments.
  • Experience with agentic AI platforms, agent hosting frameworks, and workflow orchestration tools.
  • Familiarity with the broader LLM ecosystem, including model providers, orchestration libraries, and governance frameworks.
  • Experience implementing AI gateways, centralized model access controls, policy layers, or audit systems.
  • Experience with FinOps tooling and cost-allocation models for platform services.
  • Experience shipping developer experience capabilities such as SDKs, CLIs, templates, and documentation.
  • Experience with manufacturing systems and industrial data sources such as SCADA, Data Historian, MES, ERP, and LIMS.
  • Experience with cloud and data platforms including AWS, Databricks, Apache Spark, PySpark, Scala, Python, and SQL.
  • Experience with real-time and event-driven integration using Apache Kafka, Debezium, or similar streaming technologies.
  • Experience with GenAI and MLOps capabilities such as MLflow, model serving, experiment tracking, prompt management, deployment automation, and governance.
  • Experience with AI application frameworks and orchestration tools such as LangChain, LangGraph, LlamaIndex, DSPy, Amazon Bedrock, and OpenAI APIs.
  • Experience with knowledge retrieval patterns including RAG, embeddings, vector databases, knowledge graphs, and metadata-driven search.
  • Experience with production engineering practices including Kubernetes, containers, microservices, API gateway patterns, CI/CD, automated testing, and observability.
  • Experience with Agile/SAFe delivery using JIRA, Confluence, and DevOps tooling.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A broad pipeline targets heart disease, obesity, rare disease, inflammation, and cancer.
  • Global reach across roughly 100 countries supports scale and diversification.
  • Legacy cash flows from mature biologics fund new medicine development.

What critics are saying

  • Enbrel faces pricing pressure after Colorado's 70% price-cap challenge.
  • Recent Corlanor and Sensipar recalls expose manufacturing and quality-control weaknesses.
  • Biosimilar competition threatens mature biologics and compresses future margins.

What makes Amgen unique

  • Amgen combines biologics discovery, manufacturing, and commercialization under one integrated platform.
  • Its portfolio spans oncology, cardiovascular, inflammation, bone health, and rare disease.
  • Human genetics and biology guide its drug discovery strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.